Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Cystic fibrosis

Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Cystic fibrosis is an autosomal recessive disease caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is an ion channel protein that transports chloride ions across the membranes of cells that line airways, glands, and the digestive tract.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence of Cystic fibrosis in a range of 0.72 to 0.76 per 10,000 in the 27 EU countries, whereas prevalence is reported to be 0.81 in the United States.

Competitive landscape of Cystic fibrosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cystic fibrosis 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cystic fibrosis market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 VX-121 & VX-561 Vertex Pharmaceuticals Incorporated Phase 3
2 Galicaftor AbbVie Phase 2
3 P-1037 Parion Sciences Phase 2
4 MP-376 Horizon Pharma USA, Inc. Phase 3
5 AIR DNase Protalix Phase 1
6 Ultrase® MT20 Forest Laboratories Phase 3
7 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
8 BI 443651 Boehringer Ingelheim Phase 1
9 ALX-009 Alaxia SAS Phase 1
10 POL6014 Santhera Pharmaceuticals Phase 2
11 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
12 ELX/TEZ/IVA Vertex Pharmaceuticals Incorporated Phase 3
13 Ataluren (PTC124®) PTC Therapeutics Phase 3
14 Liposomal amikacin for inhalation Insmed Incorporated Phase 3
15 OligoG DPI AlgiPharma AS Phase 2
16 QR-010 ProQR Therapeutics Phase 1
17 CHF 6333 Chiesi Farmaceutici S.p.A. Phase 1
18 Cysteamine NovaBiotics Ltd. Phase 2
19 AZLI Gilead Sciences Phase 3
20 Vancomycin inhalation powder Savara Inc. Phase 3
21 TOBI Novartis Pharmaceuticals Phase 3
22 AZLI Gilead Sciences Phase 3
23 MRT5005 Translate Bio, Inc. Phase 2
24 MS1819-SD AzurRx SAS Phase 2
25 SPI-1005 Sound Pharmaceuticals, Incorporated Phase 2
26 N91115 Nivalis Therapeutics, Inc. Phase 1
27 Nitric oxide Beyond Air Inc. Phase 2
28 QR-010 ProQR Therapeutics Phase 2
29 AIR DNase™ Protalix Phase 2
30 EUR-1008 (APT-1008) Forest Laboratories Phase 3